Gyre Therapeutics, Inc. (GYRE)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Gyre Pharmaceuticals	116.59M	105.76M	113.45M	102.29M
Gyre Pharmaceuticals Growth	10.24%	-6.78%	10.91%	-
Total	116.59M	105.76M	113.45M	102.29M
Total Growth	10.24%	-6.78%	10.91%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Mainland China	116.59M	105.76M	113.45M	102.29M
Mainland China Growth	10.24%	-6.78%	10.91%	-
Total	116.59M	105.76M	113.45M	102.29M
Total Growth	10.24%	-6.78%	10.91%	-

Data Source: S&P Global Market Intelligence Last updated: May 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 17, 2026

Data Sources Report a data error